Focal Healthcare (OBIO Pre-CAAP 2015) announced it has received both FDA 510(k) clearance and Health Canada approval for its Fusion Bx™ 2.0 prostate biopsy solution, which is now available for sale in the United States and Canada.
Focal Healthcare Announces FDA and Health Canada Clearance
Previous
Previous
Conavi Medical Awarded Joule Innovation Grant
Next
Next